These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 30980851)
1. Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model. Xiong Z; Fujita Y; Zhang K; Pu Y; Chang L; Ma M; Chen J; Hashimoto K Behav Brain Res; 2019 Aug; 368():111904. PubMed ID: 30980851 [TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of anti-RANKL antibody in depression-like phenotype, inflammatory bone markers, and bone mineral density in male susceptible mice after chronic social defeat stress. Zhang J; Fujita Y; Chang L; Pu Y; Qu Y; Wang S; Hashimoto K Behav Brain Res; 2020 Feb; 379():112397. PubMed ID: 31790783 [TBL] [Abstract][Full Text] [Related]
3. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Zhang K; Toki H; Fujita Y; Ma M; Chang L; Qu Y; Harada S; Nemoto T; Mizuno-Yasuhira A; Yamaguchi JI; Chaki S; Hashimoto K Psychopharmacology (Berl); 2018 Nov; 235(11):3177-3185. PubMed ID: 30215218 [TBL] [Abstract][Full Text] [Related]
4. Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model. Zhang K; Fujita Y; Hashimoto K Sci Rep; 2018 Mar; 8(1):4007. PubMed ID: 29507385 [TBL] [Abstract][Full Text] [Related]
5. Role of Inflammatory Bone Markers in the Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model. Zhang K; Ma M; Dong C; Hashimoto K Int J Neuropsychopharmacol; 2018 Nov; 21(11):1025-1030. PubMed ID: 30032169 [TBL] [Abstract][Full Text] [Related]
6. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Chou D; Peng HY; Lin TB; Lai CY; Hsieh MC; Wen YC; Lee AS; Wang HH; Yang PS; Chen GD; Ho YC Neuropharmacology; 2018 Sep; 139():1-12. PubMed ID: 29953886 [TBL] [Abstract][Full Text] [Related]
8. (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Yamaguchi JI; Toki H; Qu Y; Yang C; Koike H; Hashimoto K; Mizuno-Yasuhira A; Chaki S Neuropsychopharmacology; 2018 Aug; 43(9):1900-1907. PubMed ID: 29802366 [TBL] [Abstract][Full Text] [Related]
9. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2 Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184 [TBL] [Abstract][Full Text] [Related]
10. Lack of rapid antidepressant effects of Kir4.1 channel inhibitors in a chronic social defeat stress model: Comparison with (R)-ketamine. Xiong Z; Zhang K; Ishima T; Ren Q; Ma M; Pu Y; Chang L; Chen J; Hashimoto K Pharmacol Biochem Behav; 2019 Jan; 176():57-62. PubMed ID: 30502360 [TBL] [Abstract][Full Text] [Related]
11. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360 [TBL] [Abstract][Full Text] [Related]
12. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. Zanos P; Highland JN; Liu X; Troppoli TA; Georgiou P; Lovett J; Morris PJ; Stewart BW; Thomas CJ; Thompson SM; Moaddel R; Gould TD Br J Pharmacol; 2019 Jul; 176(14):2573-2592. PubMed ID: 30941749 [TBL] [Abstract][Full Text] [Related]
13. BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model. Ju L; Yang J; Zhu T; Liu P; Yang J BMC Psychiatry; 2022 Mar; 22(1):182. PubMed ID: 35291971 [TBL] [Abstract][Full Text] [Related]
14. Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions. Chou D Neuropharmacology; 2020 Jun; 170():108068. PubMed ID: 32222405 [TBL] [Abstract][Full Text] [Related]
15. Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice. Yamagishi A; Ikekubo Y; Mishina M; Ikeda K; Ide S J Pharmacol Sci; 2024 Mar; 154(3):203-208. PubMed ID: 38395521 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine. Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046 [TBL] [Abstract][Full Text] [Related]
18. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( Highland JN; Morris PJ; Zanos P; Lovett J; Ghosh S; Wang AQ; Zarate CA; Thomas CJ; Moaddel R; Gould TD J Psychopharmacol; 2019 Jan; 33(1):12-24. PubMed ID: 30488740 [TBL] [Abstract][Full Text] [Related]
19. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. Chen BK; Luna VM; LaGamma CT; Xu X; Deng SX; Suckow RF; Cooper TB; Shah A; Brachman RA; Mendez-David I; David DJ; Gardier AM; Landry DW; Denny CA Neuropsychopharmacology; 2020 Aug; 45(9):1545-1556. PubMed ID: 32417852 [TBL] [Abstract][Full Text] [Related]
20. Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine. Shirayama Y; Hashimoto K Int J Neuropsychopharmacol; 2018 Jan; 21(1):84-88. PubMed ID: 29155993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]